VELTASSA
Peakpatiromer
NDAORALPOWDER
Approved
Oct 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
5/8 — Partial
VELTASSA (patiromer) is potassium ion binding activity [moa]. First approved in 2015.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VELTASSA (patiromer) is an oral powder potassium binder approved in October 2015 for the treatment of hyperkalemia. It works through potassium ion binding activity in the gastrointestinal tract, reducing serum potassium levels without systemic absorption. The drug represents a non-emergent treatment option for patients who cannot tolerate or have contraindications to other potassium-lowering therapies, including those with chronic kidney disease or heart failure.
$0.2BPart D
7.4 years to LOEMechanism of Action
Potassium Ion Binding Activity
Pharmacologic Class:
Potassium Binder
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
Started Apr 2019
1,195 enrolled
Hyperkalemia
Evaluation of Patiromer in Heart Failure Patients
Started Apr 2009
120 enrolled
HyperkalemiaHeart Failure
Why This Matters for Your Career
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.